<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911092</url>
  </required_header>
  <id_info>
    <org_study_id>2006-13</org_study_id>
    <nct_id>NCT00911092</nct_id>
    <nct_alias>NCT00932815</nct_alias>
  </id_info>
  <brief_title>Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer</brief_title>
  <acronym>COL06-13</acronym>
  <official_title>Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scope of the trial is to predict the early complete clinical response to exclusive
      concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per-
      therapeutic proteomic profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further informations will be provided by Centre Oscar Lambret.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry</measure>
    <time_frame>15 weeks after the end of irradiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Initial complete clinical response</measure>
    <time_frame>15 weeks after the end of irradiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolonged clinical response at one year</measure>
    <time_frame>One year after the end of irradiation</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy (Fluorouracil and Cisplatin)</intervention_name>
    <description>At weeks 1, 5, 8 and 11
Day 1 to day 4: Fluorouracil 1 gr/m²/day
Day 1 or 2: Cisplatin 75 mg/m²</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a),
             histologically proven

          -  Treated by exclusive concomitant radiochemotherapy

          -  Written informed consent

        Exclusion Criteria:

          -  Presence of a second uncontrolled cancer

          -  Metastatic carcinoma

          -  Metastatic disease, except cervical lymphnodes... (M1a)

          -  In situ carcinoma

          -  Eso-gastric junction cancer (Siewert II ou III)

          -  Inclusion in a clinical trial with an experimental drug during the study and until 15
             weeks after the end of radiotherapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ADENIS Antoine, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François BACLESSE</name>
      <address>
        <city>Caen</city>
        <zip>14046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2009</study_first_submitted>
  <study_first_submitted_qc>May 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2009</study_first_posted>
  <last_update_submitted>December 30, 2011</last_update_submitted>
  <last_update_submitted_qc>December 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oesophageal cancer</keyword>
  <keyword>exclusive concomitant radiochemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

